ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Hepatitis B Virus Prophylaxis and Treatment among Hematopoietic Stem Cell Transplant Recipients: Impact on Engraftment and Outcomes

B. Buzo1, J. Fernandes Ramos2, R. Marques Rossetti3, N. Salles4, A. Mendrone-Junior4, V. Rocha3, A. de Seixas Santos Nastri5

1Division of Infectious Diseases, University of Alberta, Edmonton, AB, Canada, 2Division of Infectious Diseases and Division of Hematology, University of Sao Paulo, Sao Paulo, Brazil, 3Division of Hematology, University of Sao Paulo, Sao Paulo, Brazil, 4Fundacao Pro-Sangue, Sao Paulo, Brazil, 5Division of Infectious Diseases, University of Sao Paulo, Sao Paulo, Brazil

Meeting: 2020 American Transplant Congress

Abstract number: A-206

Keywords: Bone marrow transplantation, Engraftment, Hepatitis B, Prophylaxis

Session Information

Session Name: Poster Session A: Non-Organ Specific: Viral Hepatitis

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Hepatitis B virus infection is a worldwide concern with a broad distribution. It can reactivate in immunocompromised populations such as solid organ and hematopoietic stem cell transplant (HSCT) recipients, leading to acute hepatic failure. Different risk factors are known for higher risk of reactivation and entecavir, tenofovir, and lamivudine are often used for prophylaxis in this context. However, data regarding the impact of antiviral drugs in neutrophil and platelet engraftment are still scarce and complicates the management of viral hepatitis post-HSCT.

*Methods: We performed a single-center retrospective observational study of adult HSCT from 2010 to 2017, aiming to describe outcomes related to antiviral treatment for HBV and the impact on platelet and neutrophil recovery after transplant. Participants were adults with positive screening for Hepatitis B infection, confirmed by a second serology test. A total of 1132 hematopoietic stem cell recipients were evaluated.

*Results: 86 patients were confirmed to have HBV infection in the cohort, mostly resolved or isolated anti-HBc. With regards to prophylaxis, 19 patients underwent HSCT using HBV antiviral drugs, from which 2 were HBeAg-positive, 3 were HBeAg-negative and HBV-DNA was only detectable in 3 of them. Moreover, one patient had an occult HBV infection. As for therapy, 9 patients were prescribed entecavir, 6 patients lamivudine, 2 tenofovir and 2 were on a combination of tenofovir + lamivudine (due to HIV co-infection). Reverse seroconversion was not identified in any patients receiving antiviral therapy, although it was detected in one patient with occult hepatitis B and in another with resolved infection. No severe side effects occurred in the treated group, and there was no significant delay in neutrophil or platelet engraftment when compared to patients without antiviral use. The factors linked to increased mortality were: age at transplant over 50 years, allogeneic transplant and myeloablative conditioning regimens. Interestingly, the presence of HBsAg or detectable HBV-DNA was not related to worse outcomes, nor the use of Rituximab.

*Conclusions: HBV serology, ALT and HBV-DNA monitoring are essential to prevent hepatic flares, even in populations with chronic inactive hepatitis due to the possibility of late seroconversion. Antiviral prophylaxis did not cause any important side effects or biochemical abnormalities that would prompt discontinuation, and its use was not related to later neutrophil and platelet engraftment.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Buzo B, Ramos JFernandes, Rossetti RMarques, Salles N, Mendrone-Junior A, Rocha V. Hepatitis B Virus Prophylaxis and Treatment among Hematopoietic Stem Cell Transplant Recipients: Impact on Engraftment and Outcomes [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/hepatitis-b-virus-prophylaxis-and-treatment-among-hematopoietic-stem-cell-transplant-recipients-impact-on-engraftment-and-outcomes/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences